Cargando…

Midbrain catecholaminergic neurons co-express α-synuclein and tau in progressive supranuclear palsy

Objective: To analyze the frequency and distribution of α-synuclein deposits in progressive supranuclear palsy (PSP). Methods: The brains of 25 cases of pathologically confirmed PSP were evaluated with immunohistochemistry for α-synuclein and tau. Multiple immunofluorescent stains were applied to an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Erro Aguirre, María Elena, Zelaya, María Victoria, Sánchez Ruiz de Gordoa, Javier, Tuñón, María Teresa, Lanciego, José Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356077/ https://www.ncbi.nlm.nih.gov/pubmed/25814937 http://dx.doi.org/10.3389/fnana.2015.00025

Ejemplares similares

Bilateral, vertical supranuclear gaze palsy following unilateral midbrain infarct
por: Yang, Yunfei, et al.
Publicado: (2020)

Immunohistochemical Study of Mitochondrial Ferritin in the Midbrain of Patients with Progressive Supranuclear Palsy
por: Abu Bakar, Zulzikry Hafiz, et al.
Publicado: (2021)

Energy expenditure, body composition and dietary habits in progressive supranuclear palsy
por: Picillo, Marina, et al.
Publicado: (2021)

Psychometric properties of the Beck Depression Inventory‐II in progressive supranuclear palsy
por: Cuoco, Sofia, et al.
Publicado: (2021)

Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration
por: Martínez-Maldonado, Alejandra, et al.
Publicado: (2021)

Gait Analysis in Progressive Supranuclear Palsy Phenotypes
por: Picillo, Marina, et al.
Publicado: (2021)

Frequency and imaging correlates of neuropsychiatric symptoms in Progressive Supranuclear Palsy
por: Cuoco, Sofia, et al.
Publicado: (2023)

Midbrain/pons area ratio and clinical features predict the prognosis of progressive Supranuclear palsy
por: Cui, Shi-Shuang, et al.
Publicado: (2020)

Characterization of tau oligomeric seeds in progressive supranuclear palsy
por: Gerson, Julia E, et al.
Publicado: (2014)

Distribution patterns of tau pathology in progressive supranuclear palsy
por: Kovacs, Gabor G., et al.
Publicado: (2020)

SUMO1 Modification of Tau in Progressive Supranuclear Palsy
por: Takamura, Hironori, et al.
Publicado: (2022)

Uncovering clinical and radiological asymmetry in progressive supranuclear palsy—Richardson’s syndrome
por: Picillo, Marina, et al.
Publicado: (2022)

Clinical use of SAND battery to evaluate language in patients with Progressive Supranuclear Palsy
por: Picillo, Marina, et al.
Publicado: (2019)

Cell-specific MAPT gene expression is preserved in neuronal and glial tau cytopathologies in progressive supranuclear palsy
por: Forrest, Shelley L., et al.
Publicado: (2023)

Glucocerebrosidase Gene Therapy Induces Alpha-Synuclein Clearance and Neuroprotection of Midbrain Dopaminergic Neurons in Mice and Macaques
por: Sucunza, Diego, et al.
Publicado: (2021)

Latent trait modeling of tau neuropathology in progressive supranuclear palsy
por: Kouri, Naomi, et al.
Publicado: (2021)

Accurate digital quantification of tau pathology in progressive supranuclear palsy
por: Pansuwan, Tanrada, et al.
Publicado: (2023)

Association of MRI Measures With Disease Severity and Progression in Progressive Supranuclear Palsy
por: Picillo, Marina, et al.
Publicado: (2020)

Retinal thinning in progressive supranuclear palsy: differences with healthy controls and correlation with clinical variables
por: Picillo, Marina, et al.
Publicado: (2022)

Utility of the Midbrain Tegmentum Diameter in the Differential Diagnosis of Progressive Supranuclear Palsy from Idiopathic Parkinson's Disease
por: Kim, Yool-Hee, et al.
Publicado: (2015)

Tau burden and the functional connectome in Alzheimer’s disease and progressive supranuclear palsy
por: Cope, Thomas E, et al.
Publicado: (2018)

Does the Anti‐Tau Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? No
por: Höglinger, Günter U.
Publicado: (2021)

Autonomic dysfunction in progressive supranuclear palsy
por: Baschieri, Francesca, et al.
Publicado: (2022)

Presence of Skin α-Synuclein Deposits Discriminates Parkinson’s Disease from Progressive Supranuclear Palsy and Corticobasal Syndrome
por: Giannoccaro, Maria Pia, et al.
Publicado: (2022)

Is the Phenotype Designation by PSP-MDS Criteria Stable Throughout the Disease Course and Consistent With Tau Distribution?
por: Sánchez-Ruiz de Gordoa, Javier, et al.
Publicado: (2022)

Zolpidem in Progressive Supranuclear Palsy
por: Dash, Sandip K.
Publicado: (2013)

Genetics of Progressive Supranuclear Palsy
por: Im, Sun Young, et al.
Publicado: (2015)

Falls in Progressive Supranuclear Palsy
por: Brown, Fraser S., et al.
Publicado: (2019)

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

Contribution of the astrocytic tau pathology to synapse loss in progressive supranuclear palsy and corticobasal degeneration
por: Briel, Nils, et al.
Publicado: (2020)

Distinct subcortical tau burden: The tau pallido‐claustral ratio separates progressive supranuclear palsy and corticobasal degeneration
por: Zhao, Chelsey ShengQi, et al.
Publicado: (2021)

Atrophy in midbrain & cerebral/cerebellar pedunculi is characteristic for progressive supranuclear palsy – A double-validation whole-brain meta-analysis
por: Albrecht, Franziska, et al.
Publicado: (2019)

New perspectives on catecholaminergic regulation of executive circuits: evidence for independent modulation of prefrontal functions by midbrain dopaminergic and noradrenergic neurons
por: Chandler, Daniel J., et al.
Publicado: (2014)

Heavy metals contaminating the environment of a progressive supranuclear palsy cluster induce tau accumulation and cell death in cultured neurons
por: Alquezar, Carolina, et al.
Publicado: (2020)

Pathological tau signatures and nuclear alterations in neurons, astrocytes and microglia in Alzheimer's disease, progressive supranuclear palsy, and dementia with Lewy bodies
por: Montalbano, Mauro, et al.
Publicado: (2022)

Calbindin content and differential vulnerability of midbrain efferent dopaminergic neurons in macaques
por: Dopeso-Reyes, Iria G., et al.
Publicado: (2014)

Polyglucosan bodies in medullary catecholaminergic neurones in SUDEP
por: Patodia, Smriti, et al.
Publicado: (2021)

Recruitment of dorsal midbrain catecholaminergic pathways in the recovery from nerve injury evoked disabilities
por: Mor, David, et al.
Publicado: (2015)

Associations of mitochondrial genomic variation with corticobasal degeneration, progressive supranuclear palsy, and neuropathological tau measures
por: Valentino, Rebecca R., et al.
Publicado: (2020)

Combination of midbrain-to-pontine ratio and cardiac MIBG scintigraphy to differentiate Parkinson's disease from multiple system atrophy and progressive supranuclear palsy
por: Sakuramoto, Hirotaka, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ub25gaifse4ttnhp08t6pt5vbg